Patent ID: 11919963
Assignee: INHIBRX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An immunoconjugate comprising a polypeptide comprising at least one VHH domain that binds CD123 and a cytotoxic agent, wherein at least one VHH domain that binds CD123 comprises:
a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 3; a CDR2 comprising the amino acid sequence of SEQ ID NO: 4; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 5, and wherein the VHH domain comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 26;
b) a CDR1 comprising the amino acid sequence of SEQ ID NO: 42; a CDR2 comprising the amino acid sequence of SEQ ID NO: 43; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 44, and wherein the VHH domain comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 29 or 30;
c) a CDR1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 9or 38, and wherein the VHH domain comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 27;
d) a CDR1 comprising the amino acid sequence of SEQ ID NO: 15; a CDR2 comprising the amino acid sequence of SEQ ID NO: 16; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 17, and wherein the VHH domain comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 28; or
e) a CDR1 comprising the amino acid sequence of SEQ ID NO: 23; a CDR2 comprising the amino acid sequence of SEQ ID NO: 24or 94; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 25, and wherein the VHH domain comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 31, 32 or 92.